Reliis

Reliis is an Australian clinical-stage pharmaceutical company specializing in the reformulation of established, off-patent medications to address significant unmet clinical needs. The company's lead program, RLS-2202 (formerly RLS-2201), is a proprietary intravenous formulation of the atypical antipsychotic quetiapine designed for the rapid treatment of acute and agitated delirium in intensive care, aged care, and palliative care settings. By leveraging the FDA's 505(b)(2) and EMA abridged regulatory pathways, Reliis aims to deliver a faster, lower-risk route to market compared to traditional drug discovery. In January 2026, Reliis was acquired by Patrys Limited (ASX: PAB), which is now advancing RLS-2202 through Phase 1A clinical development.